ATyr Pharma's Lead Therapeutic Candidate Efzofitimod For Pulmonary Sarcoidosis To Be Featured In Best Of CHEST Journals At CHEST 2024 Annual Meeting October 6 – 9, 2024
ATyr Pharma's Lead Therapeutic Candidate Efzofitimod For Pulmonary Sarcoidosis To Be Featured In Best Of CHEST Journals At CHEST 2024 Annual Meeting October 6 – 9, 2024
atyr pharma的主要治疗候选药物Efzofitimod用于肺结节性硬化的特色板块将在CHESt杂志2024年度会议的最佳期刊中展示，时间为2024年10月6日至9日。
aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company's lead therapeutic candidate, efzofitimod, will be featured in the Best of CHEST Journals session at the CHEST 2024 Annual Meeting, which is scheduled to take place October 6 – 9, 2024, in Boston, MA.
aTyr Pharma公司（纳斯达克股票代码：ATYR）（“aTyr”或“公司”）是一家临床阶段生物技术公司，致力于从其专有tRNA合成酶平台发现和开发首创药物。今天宣布，公司的领先治疗候选药物efzofitimod将在CHESt 2024年度会议上的Best of CHESt期刊专栏中亮相，该会议定于2024年10月6日至9日在马萨诸塞州波士顿举行。
资讯热榜
更新时间